Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer

Table 5 Clinical factors for recurrence within 1 year

		No recurrence	Recurrence	p value
		(n = 39)	(n = 35)
Age (years)		67	70	0.105
Sex, n	Male	29	22
	Female	10	13	0.286
Brinkman index		800	870	0.795
Pulmonary fibrosis score, n	0–1	37	32
	≥ 2	2	3	0.448
Pulmonary emphysema score		0	1	0.255
LDH (U/L)		192	214	0.086
CRP (mg/dL)		0.22	0.54	0.089
HbA1c (%)		5.9	5.8	0.484
Glucose (mg/dL)		103	105	0.803
KL-6 (U/mL)		324	288	0.545
Clinical stage of lung cancer		IIIB	IIIB	0.029
Chemotherapy, n	–	7	8
	+	32	27	0.814
Durvalumab, n	–	21	30
	+	18	5	0.003
V ₂₀ (%)		20.3	24.1	0.378
V ₅ (%)		34.6	39.0	0.458
MLD (Gy)		11.8	13.0	0.414
Vs5 (cc)		2183	1905	0.570
Lung volume (cc)		3389	3369	0.721
ILD onset timing (days)		90.5	85.0	0.582

ISSN: 1748-717X